Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disseminated tumor cells: are they ready for clinical use?
Braun S, Vogl FD, Schneitter A, Egle D, Auer D, Lang M, Marth C. Braun S, et al. Among authors: egle d. Breast. 2007 Dec;16 Suppl 2:S51-4. doi: 10.1016/j.breast.2007.07.006. Breast. 2007. PMID: 17983941 Review.
Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs).
Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper EM, Sperner-Unterweger B, Holzner B. Oberguggenberger A, et al. Among authors: egle d. Breast Cancer Res Treat. 2011 Jul;128(2):553-61. doi: 10.1007/s10549-011-1378-5. Epub 2011 Feb 11. Breast Cancer Res Treat. 2011. PMID: 21311968
HE4 is an independent prognostic marker in endometrial cancer patients.
Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A. Mutz-Dehbalaie I, et al. Among authors: egle d. Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21. Gynecol Oncol. 2012. PMID: 22525819
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: egle d. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31. Lancet. 2015. PMID: 26040499 Clinical Trial.
Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: A patient-reported outcome study.
Oberguggenberger A, Sztankay M, Morscher RJ, Sperner-Unterweger B, Weber I, Hubalek M, Kemmler G, Zschocke J, Martini C, Egle D, Dünser M, Gamper E, Meraner V. Oberguggenberger A, et al. Among authors: egle d. J Psychosom Res. 2016 Oct;89:39-45. doi: 10.1016/j.jpsychores.2016.08.005. Epub 2016 Aug 8. J Psychosom Res. 2016. PMID: 27663109
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: egle d. Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19. Lancet Oncol. 2019. PMID: 30795951 Clinical Trial.
91 results